Human medicines European public assessment report (EPAR): Tenkasi (previously Orbactiv), oritavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/03/2015, Revision: 14, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,- 14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]- oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyldimethyl-phosphinate (MK-8669, or AP23573), decision type: , therapeutic area: , PIP number: P/2/2010

Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 11-14 September 2023

Agenda of the HMPC meeting 18-20 September 2023

Opinion/decision on a Paediatric investigation plan (PIP): Etrasimod L-arginine, decision type: , therapeutic area: , PIP number: P/0409/2022

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, Amsterdam, from 28/06/2023 to 28/06/2023

10th anniversary of European Medicines Agency (EMA) Healthcare Professionals' (HCPWP) Working Party meeting, Amsterdam, from 27/06/2023 to 27/06/2023

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) Working Party meeting, Amsterdam, from 27/06/2023 to 27/06/2023

Opinion/decision on a Paediatric investigation plan (PIP): sotatercept, decision type: , therapeutic area: , PIP number: P/0414/2022

Opinion/decision on a Paediatric investigation plan (PIP): Adrenaline (epinephrine), decision type: , therapeutic area: , PIP number: P/0404/2022